Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927640 · ClinicalTrials.gov registry record · Early Phase 1
Dexmedetomidine for Reversal of Cocaine's Effects on the Heart
A Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 115
- Enrollment target
NCT01927640 is a Early Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 115 participants.
The verdict
NCT01927640, a Early Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
This study will use myocardial contrast echocardiography performed during a continuous intravenous infusion of Definity microbubbles (Perflutren lipid microbubbles) to determine if dexmedetomidine (an intravenous central sympatholytic drug) can reverse all the cardiovascular effects of low-dose intranasal cocaine-including vasoconstriction in the coronary microcirculation-both in cocaine-naïve and non-treatment seeking cocaine-addicted subjects.
Interventions
- DRUG Dexmedetomidine
- DRUG Normal Saline
- DRUG Intranasal cocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2014-01-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927640
The ClinicalTrials.gov registry entry for NCT01927640 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexmedetomidine is the first listed.
NCT01927640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927640 about?
NCT01927640 is a clinical study titled "Dexmedetomidine for Reversal of Cocaine's Effects on the Heart". This study will use myocardial contrast echocardiography performed during a continuous intravenous infusion of Definity microbubbles (Perflutren lipid microbubbles) to determine if dexmedetomidine (an intravenous central sympatholytic drug) can reverse all the cardiovascular effects of low-dose intr...
What is the current status of trial NCT01927640?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 115 participants. The study started on 2013-02-01. Estimated completion is 2014-01-15.
What interventions are being tested in trial NCT01927640?
The interventions under investigation include: Dexmedetomidine (DRUG), Normal Saline (DRUG), Intranasal cocaine (DRUG).
Who is sponsoring clinical trial NCT01927640?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.